Sign in
CompletedPhase 1

A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza

Key facts

Who runs it
Pfizer
Where
Hollywood, New Haven, and New York, United StatesSee the 3 sites
Trial code
Status
Completed
Phase
Phase 1
People taking part
157 people enrolled
Started
13 Dec 2023
Ended
23 Sept 2025
Type of study
Interventional, 10 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • pdmFlu vaccine
  • Placebo
  • Licensed influenza vaccine
Record updated
23 February 2026

Who can take part

Age
18 years to 84 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study

Who cannot take part

  • Does not meet seasonal influenza vaccine requirements per cohort

Where in United States

  • Research Centers of AmericaHollywood, United States
  • Pfizer Clinical Research Unit - New HavenNew Haven, United States
  • NYU Langone HealthNew York, United States

About the trial

What the trial wants to find out

The purpose of this study is to learn about the safety and effects of the study vaccine for the possible prevention of influenza. Influenza is a disease that can spread easily from one person to another and cause body aches, fever, cough, and other symptoms. The study vaccine is called Pandemic Influenza modRNA (pdmFlu) Vaccine.

Read full original descriptionShow less

This study is seeking for participants who are:

* between the ages of 18 to 49 years old or 65 to 84 years old. * willing and able to follow with all scheduled visits, treatment plan, laboratory tests, lifestyle changes, and other study procedures. * healthy as confirmed by medical history, physical examinations, and the study doctor. * capable of signing informed consent.

Participants will receive either:

* the pdmFlu vaccine, * a licensed influenza vaccine * a placebo. A placebo does not have any medicine in it but looks just like the study medicine.

Participants will not know which vaccine they receive. Participants will receive the study vaccines as a single shot in the arm. The study will compare participant experiences to help understand if the pdmFlu vaccine is safe and effective. Participants will take part in this study for up to 13 months. During this time, the participants will receive the study vaccine and take part in follow-up visits.

The 10 groups in the trial

  • pdmFlu vaccine 1Treatment being tested

    Treatment: pdmFlu vaccine

  • pdmFlu vaccine 2Treatment being tested

    Treatment: pdmFlu vaccine

  • pdmFlu vaccine 3Treatment being tested

    Treatment: pdmFlu vaccine

  • pdmFlu vaccine 4Treatment being tested

    Treatment: pdmFlu vaccine

  • pdmFlu vaccine 5Treatment being tested

    Treatment: pdmFlu vaccine

  • pdmFlu vaccine 6Treatment being tested

    Treatment: pdmFlu vaccine

  • pdmFlu vaccine 7Treatment being tested

    Treatment: pdmFlu vaccine

  • pdmFlu vaccine 8Treatment being tested

    Treatment: pdmFlu vaccine

  • PlaceboPlacebo, for comparison
  • Licensed influenza vaccineExisting treatment, for comparison

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A PHASE 1, RANDOMIZED, OBSERVER-BLIND, DOSE-RANGING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY ADULTS
Record updated
23 February 2026